Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Non-Current Deffered Revenue data on record, last reported at $8.8 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 27.12% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $8.8 million, down 27.12%, while the annual FY2025 figure was $8.8 million, 27.12% down from the prior year.
  • Non-Current Deffered Revenue reached $8.8 million in Q4 2025 per TGTX's latest filing, up from $8.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $16.2 million in Q3 2024 and bottomed at $190000.0 in Q3 2023.
  • Average Non-Current Deffered Revenue over 5 years is $3.5 million, with a median of $552000.0 recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 8408.42% in 2024, then crashed 55.46% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $457000.0 in 2021, then tumbled by 33.26% to $305000.0 in 2022, then soared by 1872.46% to $6.0 million in 2023, then surged by 100.88% to $12.1 million in 2024, then decreased by 27.12% to $8.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $8.8 million in Q4 2025, $8.3 million in Q3 2025, and $1.7 million in Q2 2025.